[1] |
Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study [J]. Cancer, 2007, 110(6):1376-1384.
|
[2] |
Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group [J]. Semin Nephrol, 2010, 30(6):548-556.
|
[3] |
Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency [J]. Eur J Cancer, 2007, 43(1):14-34.
|
[4] |
Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients [J]. Ann Oncol, 2010, 21(7):1395-1403.
|
[5] |
Rengelshausen J, Hull WE, Schwenger V, et al. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis [J]. Am J Kidney Dis, 2002, 39(2):E10.
|
[6] |
Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients [J]. Cancer Chemother Pharmacol, 2002, 49(3):225-234.
|
[7] |
Jhaveri KD, Flombaum C, Shah M, et al. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis [J]. J Oncol Pharm Pract, 2012, 18(1):140-147.
|
[8] |
Labaye J, Sarret D, Duvic C, et al. Renal toxicity of oxaliplatin [J]. Nephrol Dial Transplant, 2005, 20(6):1275.
|
[9] |
Takimoto CH, Remick SC, Sharma S, et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group [J]. Semin Oncol, 2003, 30(4 Suppl. 15):20-25.
|
[10] |
http: //www.drugfuture.com/fda-ndc/label.aspx?ProductNDC=70860-201#s49
|
[11] |
Katsumata K, Sumi T, Wada T, et al. Oxaliplatin for metastatic colon cancer in a patient with renal failure [J]. Clin Med Oncol, 2008, 2(2):97-101.
|
[12] |
Watayo Y, Kuramochi H, Hayashi K, et al. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis [J]. Jpn J Clin Oncol, 2010, 40(4):360-364.
|
[13] |
Horimatsu T, Miyamoto S, Morita S, et al. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy [J]. Cancer Chemother Pharmacol, 2011, 68(1):263-266.
|
[14] |
Gori S, Lunardi G, Inno A, et al. Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis [J]. Clin Colorectal Cancer, 2014, 13(4):260-263.
|
[15] |
Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients [J]. Ann Oncol, 2010, 21(7):1395-1403.
|
[16] |
Ashizawa T, Iwahori T, Yokoyama T, et al. Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer [J]. Acta Med Okayama, 2010, 64(1):19.
|
[17] |
Czock D, Rasche FM, Boesler B, et al. Irinotecan in cancer patients with end-stage renal failure [J]. Ann Pharmacother, 2009, 43(2):363-369.
|
[18] |
http: //www.drugfuture.com/fda-ndc/label.aspx?ProductNDC=50242-060
|
[19] |
http: //www.drugfuture.com/fda-ndc/label.aspx?ProductNDC=0024-5840
|
[20] |
http: //www.drugfuture.com/fda-ndc/label.aspx?ProductNDC=0002-7669
|
[21] |
Cao Y, Liao C, Tan A, et al. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer [J]. Chemotherapy, 2010, 56(6):459-465.
|
[22] |
Chen P, Wang L, Li H, et al. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis [J]. Oncol Lett, 2013, 5(6):1915-1920.
|
[23] |
Nikolic-Tomasevic Z, Jelic S, Cassidy J, et al. Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis [J]. Cancer Chemother Pharmacol, 2005, 56(6):594-602.
|
[24] |
Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of chemotherapy [J]. Semin Oncol, 2006, 33(1):50-67.
|
[25] |
Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites [J]. Clin Cancer Res, 1999, 5(7):1696-1702.
|
[26] |
EB/OL] (Accessed on May 04, 2017)
URL
|
[27] |
Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction [J]. J Clin Oncol, 2002, 20(21):4303-4312.
|
[28] |
Venook AP, Enders Klein C, Fleming G, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863 [J]. Ann Oncol, 2003, 14(12):1783-1790.
|
[29] |
EB/OL] (Accessed on May 04, 2017)
URL
|
[30] |
Meyerhardt JA, Kwok A, Ratain MJ, et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2004, 22(8):1439-1446.
|
[31] |
Kramar A, Gourgou-Bourgade S, Ychou M. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan [J]. J Clin Oncol, 2004, 22(8):1439-1446.
|
[32] |
Slade JH, Alattar ML, Fogelman DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury [J]. Clin Colorectal Cancer, 2009, 8(4):225-230.
|
[33] |
Synold TW, Takimoto CH, Doroshow JH, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study [J]. Clin Cancer Res, 2007, 13(12):3660-3666.
|
[34] |
Grenader T, Goldberg A, Gabizon A. Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel [J]. Anticancer Drugs, 2009, 20(9):845-847.
|
[35] |
Fakih MG. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction [J]. Oncology, 2004, 67(3-4):222-224.
|
[36] |
EB/OL] (Accessed on May 04, 2017)
URL
|
[37] |
EB/OL] (Accessed on May 04, 2017)
URL
|
[38] |
US Food and Drug Administration (FDA)-approved prescribing information for ramucirumab available online at EB/OL] (Accessed on May 04, 2017)
URL
|
[39] |
Madbouly KM, Hussein AM, Zeid A. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis? [J]. Dis Colon Rectum, 2013, 56(5):577-585.
|
[40] |
Gervaz P, Pak-art R, Nivatvongs S, et al. Colorectal adenocarcinoma in cirrhotic patients [J]. J Am Coll Surg, 2003, 196(6):874-879.
|
[41] |
Slade JH, Alattar ML, Fogelman DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury [J]. Clin Colorectal Cancer, 2009, 8(4):225-230.
|
[42] |
Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy [J]. Ann Intern Med, 2009, 150(9):657-658.
|
[43] |
Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy [J]. J Viral Hepat, 2011, 18(12):877-883.
|
[44] |
Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? [J]. Hepatology, 2015, 61(2):703-711.
|
[45] |
Ling WH, Soe PP, Pang AS, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours [J]. Br J Cancer, 2013, 108(10):1931-1935.
|
[46] |
Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus [J]. Lancet, 1996, 347(8994):92-93.
|
[47] |
Lestuzzi C, Vaccher E, Talamini R, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk [J]. Ann Oncol, 2014, 25(5):1059-1064.
|
[48] |
Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study [J]. J Cancer Res Clin Oncol, 2008, 134(1):75-82.
|
[49] |
Saif MW, Choma A, Salamone SJ, et al. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes [J]. J Natl Cancer Inst, 2009, 101(22):1543-1552.
|
[50] |
Saif MW, Tomita M, Ledbetter L, et al. Capecitabine-related cardiotoxicity: recognition and management [J]. J Support Oncol, 2008, 6(1):41-48.
|
[51] |
Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine [J]. Cancer Chemother Pharmacol, 2006, 58(4):487-493.
|
[52] |
EB/OL] (Accessed on May 04, 2017)
URL
|
[53] |
Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) [J]. Eur J Cancer, 2008, 44(15):2204-2211.
|
[54] |
Yothers G, O′Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses [J]. J Clin Oncol, 2011, 29(28):3768-3774.
|
[55] |
EB/OL] (Accessed on May 04, 2017)
URL
|
[56] |
FDA-approved manufacturer′s package insert for bevacizumab available online at EB/OL] (Accessed on May 04, 2017)
URL
|
[57] |
Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies [J]. J Clin Oncol, 2011, 29(13):1757-1764.
|
[58] |
Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab [J]. J Clin Oncol, 2011, 29(6):632-638.
|
[59] |
FDA-approved manufacturer′s labeling information available online at EB/OL] (Accessed on May 04, 2017)
URL
|
[60] |
Sastre J, Aranda E, MassutíB, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study [J]. Crit Rev Oncol Hematol, 2009, 70(2):134-144.
|
[61] |
Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer [J]. Br J Cancer, 2006, 94(7):969-975.
|
[62] |
Folprecht G, Rougier P, Saltz L, et al. Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan(abstract #3578) [J]. Asco Meeting Abstracts, 2006, 24(18suppl):165s.
|
[63] |
Tsai HT, Marshall JL, Weiss SR, et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study [J]. Ann Oncol, 2013, 24(6):1574-1579.
|
[64] |
Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab [J]. J Natl Cancer Inst, 2007, 99(16):1232-1239.
|
[65] |
Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial [J]. Lancet, 2011, 377(9779):1749-1759.
|
[66] |
Crosara Teixeira M, Marques DF, Ferrari AC, et al. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4 [J]. Clin Colorectal Cancer, 2015, 14(1):52-57.
|